4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME
Reuters2026/08/21 15:28- 4D Molecular Therapeutics outlined a strategy centered on 4D-150, an intravitreal AAV gene therapy for wet AMD, moving into a global Phase 3 program.
- Program expansion also targets diabetic macular edema, positioning 4D-150 as a potential long-duration backbone anti-VEGF therapy.
- Presentation framed the retinal vascular anti-VEGF market at about USD 16 billion in 2025E, with wet AMD plus DME at about USD 14 billion.
- Phase 2b PRISM data cited for 4D-150 at 3E10 vg/eye showed 1 mean supplemental injection through 1 year, implying ~365+ day interval.
- Pipeline update also highlighted 4D-710 for cystic fibrosis lung disease as fully funded, with 4D-725 for A1AT lung disease funded through IND.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cambria Gold Mines FY26 Q2 net loss narrows to CAD 2.96 million
TRUMP rises nearly 8% in 24 hours, market capitalization reaches $2.037 billions
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Crypto prices
More
